You are here:

Archived: Clostridium botulinum type A neurotoxin (Botox®)


Following a resubmission

Clostridium botulinum toxin A (Botox) not recommended for use within NHS Scotland for the treatment of focal spasticity, including the treatment of wrist and hand disability due to upper limb spasticity, associated with stroke in adults.

Botox produces a localised reduction in muscle tone in patients with post-stroke hand and wrist spasticity and improves disability at least up to 12 weeks. However, there is currently very little direct evidence of cost effectiveness of this approach.

Drug Details

Drug Name: Clostridium botulinum type A neurotoxin (Botox®)
SMC Drug ID: 80/03
Manufacturer: Allergan Ltd
Indication: Focal spasticity of the wrist and hand associated with stroke in adults
BNF Category:
Sub Category: 4.9 Drugs used in Parkinsonism and related disorders
Submission Type: Resubmission
Status: Not Recommended
Date Advice Published: 10 May 2004

Current Advice

Resubmission 7 March 2011

Archived Advice

Full submission 10 November 2003